



# ACPE/J SPE2019

ISPE's 12th Asian Conference on Pharmacoepidemiology  
11-13 October 2019 Kyoto, Japan



## SATURDAY 12 OCTOBER 2019

<b>08:00-08:20</b>	<b>Welcome ceremony</b>		
<b>Room:</b>	Plenary Hall A		
<b>Chair:</b>	<b>Frank May FISPE</b> , ACPE12 Conference Co-Chair		
	<b>Koji Kawakami</b> , ACPE12 Conference Co-Chair and Local Host Committee Chair; Kyoto University, Japan <b>Almut Winterstein FISPE</b> , President, International Society for Pharmacoepidemiology; University of Florida, USA <b>Kiyoshi Kubota FISPE</b> , President, Japanese Society for Pharmacoepidemiology; NPO Drug Safety Research Unit Japan, Japan		
<b>08:30-10:00</b>	<b>Contributed papers 1 – Substance abuse, opioids and pain</b>	<b>Symposium 1 - Variability and generalizability of claims-based algorithms in pharmacoepidemiologic research: Multinational perspectives</b>	<b>Symposium 2 – Data science and Pharmacoepidemiology in the next 10 Years</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Daisuke Koide</b> , The University of Tokyo, Japan <b>Mary-Beth Ritchey FISPE</b> , RTI Health Solutions, USA	<b>Soko Setoguchi FISPE</b> , Rutgers University, USA <b>Chieko Ishiguro</b> , Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>Wei Zhou FISPE</b> , Wei Zhou, Merck Research Laboratories, USA
08:30-08:45	<b>The impact of substance abuse on healthcare resource utilization: Big data analytics using the clinical data in Hong Kong - #100</b> Yue Wei, The University of Hong Kong, China	<b>The importance of validating outcomes when using claims data</b> Brian Strom FISPE, Rutgers University, USA  <b>Operational challenges in the execution of validation studies of claims data in Japan: A review of inter-hospital variability of results from the Japan VALIDATE study</b> Cynthia de Luise, Pfizer, USA	<b>Data science and pharmacoepidemiology in RWE: What can we learn from each other and where must we differ</b> Almut G. Winterstein FISPE, University of Florida, USA  <b>Overview in the use of RWE in the drug approval process and related challenges</b> Nancy Santanello FISPE, Consultant, USA  <b>A perspective from Asia: RWE experience in Japan</b> Koji Kawakami, Kyoto University, Japan
08:45-09:00	<b>Understanding patients with substance abuse and their healthcare pathway by using bigdata approach: Towards better management in Hong Kong - #101</b> Jia Xi Zhao, The University of Hong Kong, China		
09:00-09:15	<b>The effects of more restrictive scheduling in 2018 on subsequent codeine use and harms in Australia - #102</b> Nicholas Buckley, NSW Poisons Information Centre; The University of Sydney, Australia		

09:15-09:30	<b>Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia - #103</b> Jenni Ilomäki, Monash University, Australia	<b>Validating administrative health data in Australia</b> Benjamin Daniels, University of New South Wales, Australia	
09:30-09:45	<b>A spatial-temporal analysis of adverse drug reactions due to opioid analgesic use in New South Wales - #104</b> Wei Du, Australian National University, Australia		
09:45-10:00	<b>Trend in targeted therapy in patients with rheumatoid arthritis in Korea: A time-series analysis using nationwide health insurance data, 2010-2017 - #105</b> So-Hee Park, Sungkyunkwan University, South Korea		
<b>10:00-10:30</b>	<b>Morning tea/coffee break with poster discussions</b>		
<b>Room:</b>	Plenary Hall B		
	<b>Presenters of original research within the following abstract themes will be attending their poster during the morning tea break for discussions with interested delegates.</b> Pharmacoepidemiology and traditional medicines (poster boards 364 – 382) Pharmacogenomics research and drug safety (poster boards 383 – 388) Pharmaceutical policy and administration (poster boards 389 – 391) Other related fields (poster boards 426 – 449) Evidence-based medicine (poster boards 450 – 462) Prevention of medication errors and drug misuse/abuse (poster boards 463 – 466) Rational drug use (poster boards 467 – 474) Evidence-based pharmacy (poster boards 506 – 509) Rare disease and orphan medicines (poster boards 510 – 512) Post-marketing drug effectiveness and safety evaluation (poster boards 513 – 531)		
<b>10:30-12:00</b>	<b>Contributed papers 2 – Patient management and palliative care</b>	<b>Symposium 3 - Challenges and strategies in the post market studies of Herbal and Traditional Medicine (HTM) products</b>	<b>Symposium 4 – Approaches to assess medication exposure and associated risks during pregnancy using Real-World Data</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Keisuke Matsubayashi</b> , Kyoto University, Japan <b>Nicole Pratt</b> , University of South Australia	<b>Soko Setoguchi FISPE</b> , Rutgers University, USA	<b>Kenneth Man</b> , University College London, UK; University of Hong Kong, Hong Kong <b>Keiko Asao</b> , Amgen Astellas BioPharma K.K., Japan
10:30-10:45	<b>Assessment of impact of different instructional interventions in training on inhalers amongst asthma and COPD patients - #106</b> Shilpa Palaksha, JSS College of Pharmacy, India	<b>Real-world evidence initiative in China: An overview and its application to traditional Chinese medicine</b> Xin Sun, West China Hospital, Sichuan University, China  <b>Safety regulation of herbal medicines of Korea</b> Seong-Gyu Ko, Kyung Hee University College of Korean Medicine, Korea  <b>Current registration and review of Kampo products in Japan</b> Takeshi Yoshioka, KOKANDO Co. Ltd., Japan	<b>Use of RWD and pregnancy registries in the United States to assess medication exposure and associated risks during pregnancy</b> Jeff Lange, Amgen Inc., USA  <b>Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: Population based cohort study</b> Kenneth KC Man, University College London, UK; University of Hong Kong, Hong Kong
10:45-11:00	<b>Impact of clinical pharmacist-led education on clinical and humanistic outcome of children with Thalassemia: A randomized control study - #107</b> Juny Sebastian, JSS College of Pharmacy, India		
11:00-11:15	<b>Reducing medication burden in residential aged care: Simplification of Medications Prescribed to Long-term care Residents (SIMPLER) cluster randomised controlled trial - #108</b> Jenni Ilomaki and J Simon Bell, Monash University, Australia		

11:15-11:30	<b>Efficacy of anti-emetic regimen in chemotherapy induced nausea vomiting and its impact on quality of life in pediatric cancer population - #109</b> Vanitha Rani Nagasubramanian, Sri Ramachandra Institute of Higher Education and Research, India	<b>Pharmacovigilance practice of TCM drugs: Current status, challenges, and future directions</b> Li Zhang, Dongfang Hospital, Beijing University of Chinese Medicine, China	<b>Maternal-infant link using a Japanese administrative dataset</b> Maki Ueyama, Creativ-Ceutical K.K., Japan
11:30-11:45	<b>A Delphi study on the development of a risk proportionality framework for the selection of risk minimisation interventions in Asia - #110</b> Yola Moride FISPE, Université de Montreal, Canada; Rutgers, The State University of New Jersey, USA; YOLARX Consultants, Canada		<b>Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from an administrative dataset</b> Tomofumi Ishikawa, Tohoku University, Japan
11:45-12:00	<b>The association between partner bereavement and incident psoriasis or atopic eczema: A matched cohort study - #111</b> Angel Wong, London School of Hygiene and Tropical Medicine, UK		
<b>12:00-12:30</b>	<b>Lunch</b>		
<b>Room:</b>	Plenary Hall B		
<b>12:30-13:30</b>	<b>Plenary Presentation</b>		
<b>Room:</b>	Plenary Hall A		
<b>Co-Chairs:</b>	<b>Siyan Zhan</b> , President, Chinese Society for Pharmacoepidemiology, Peking University, Beijing China <b>Hisashi Urushihara</b> , Keio University, Japan		
	<b>Pharmacoepidemiology methods: Past, present, and advice about the future - #112</b> Brian Strom FISPE, Inaugural Chancellor of Rutgers Biomedical and Health Sciences, and Executive Vice President for Health Affairs at Rutgers University. USA		
<b>13:30-15:00</b>	<b>Contributed papers 3 – Diabetes and other cardiovascular issues</b>	<b>Symposium 5 - Use of real-world evidence (RWE) in regulatory decision-making: Regulatory guidance and examples from Asia and the US</b>	<b>Contributed papers 4 – Paediatrics</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Chieko Ishiguro</b> , Pharmaceuticals and Medical Devices Agency (PMDA), Japan <b>Byung-Joo Park FISPE</b> , Seoul National University College of Medicine, Korea	<b>Darren Toh FISPE</b> , Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Almut Winterstein FISPE</b> , University of Florida, USA <b>Ju-Young Shin</b> , Sungkyunkwan University, South Korea
13:30-13:45	<b>Antipsychotics use during pregnancy and the risk of gestational diabetes: A population-based cohort study - #113</b> Zixuan Wang, UCL School of Pharmacy, UK	<b>Introduction and overview of the symposium</b> Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Association between relative age within school year and attention deficit hyperactivity disorder (ADHD), intellectual disability and depression - #119</b> Jeremy Brown, London School of Hygiene and Tropical Medicine, UK
13:45-14:00	<b>Continuation of antipsychotic medication during pregnancy and the risk of gestational diabetes: A population-based cohort study - #114</b> Zixuan Wang, UCL School of Pharmacy, UK	<b>Regulatory approach to Real-World Evidence in the United States</b> Jeremy Rassen, Aetion, Inc., USA	<b>Efficacy of pidotimod in children: A systematic review - #120</b> Qiusha Yi, Sichuan University, China
		<b>Regulation for Use of Real-World Evidence in post-marketing drug safety assessment in Japan</b>	

14:00-14:15	<b>Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes - #115</b> Stephen Wood, Monash University, Australia	Yusuke Okada, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>Antimicrobial resistant and prescribing pattern in children in Taiwan- TARPEC project - #121</b> Ching-Lan Cheng, National Cheng Kung University Hospital, Taiwan
14:15-14:30	<b>Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors: A pharmacoepidemiological-pharmacodynamic assessment through an analysis of the VigiBase® - #116</b> Faizan Mazhar, Università di Milano, Italy	<b>Use of Real-World Evidence to support drug development and regulatory decision in China</b> Jasmanda Wu, Sanofi, USA and China	<b>Patterns of methylphenidate and atomoxetine use among pediatric patients with attention-deficit/hyperactivity disorder in Taiwan from 2004 to 2017 - #122</b> Heng-Ching Liao, National Taiwan University, Taiwan
14:30-14:45	<b>The use of insulin, diabetes status, and risk of progression after first episode of acute pancreatitis: A population-based cohort study - #117</b> Jaelim Cho, University of Auckland, New Zealand	<b>Regulatory perspective and application of Real-World Evidence in Taiwan</b> Chi-Chuan Wang, National Taiwan University, Taiwan	<b>Association between methylphenidate and risk of seizure: A population-based self-controlled case series study - #123</b> Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
14:45-15:00	<b>Impact of multiple cardiovascular medication on mortality after an incidence of stroke: A 10-year cohort study - #118</b> Tiantian Ma, UCL School of Pharmacy, UK	<b>Panel Discussion</b> Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>Comparative effect of four antimalarial treatments on haematocrit in children in Southwest Nigeria - #124</b> Zacchaeus Olofin, University of Ibadan, Nigeria
<b>15:00-15:45</b>	<b>Afternoon tea/coffee break with poster discussions</b>		
<b>Room:</b>	Plenary Hall B		
	<b>Presenters of original research within the following abstract themes will be attending their poster during the afternoon tea break for discussions with interested delegates.</b> Pharmacoepidemiology and Pharmacovigilance research methods (poster boards 332 – 363) Drug utilization evaluation studies (poster boards 392 – 425) Drug safety risk monitoring, evaluation and prevention (poster boards 475 – 505)		
<b>15:45-17:15</b>	<b>Contributed papers 5 - Cardiovascular and liver issues</b>	<b>Symposium 6 - Japan In Real Life: Data, evidence and an evolving regulatory framework for Pharmacovigilance</b>	<b>Contributed papers 6 - Dementia and older person issues</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Tsugumichi Sato</b> , Tokyo University of Science, Japan <b>Vincent Lo Re</b> , University of Pennsylvania, USA	<b>Robert Reynolds FISPE</b> , GSK R&D, USA	<b>Hisashi Urushihara</b> , Keio University, Japan <b>Takuhiro Yamaguchi</b> , Tohoku University, Japan
15:45-16:00	<b>Comparative risks of cardiovascular events associated with anti-VEGF therapy in real-life patients with macular diseases in Taiwan - #125</b> Wan-Ju Lee, National Cheng Kung University, Taiwan	<b>Introduction: Evolving pharmacovigilance regulations in Japan</b> Robert Reynolds FISPE, GSK R&D, USA	<b>Does statin use change in relation to the initiation of dementia medicine? Analysis of the Australian pharmacy claims data - #131</b> Leonie Picton, Monash University, Australia
16:00-16:15	<b>Acute kidney injury associated with non-steroidal anti-inflammatory drugs and concomitant use of renin-angiotensin system inhibitors and diuretics: A case-crossover study - #126</b> Shao-En Weng, National Taiwan University, Taiwan	<b>Real world data-driven evidence: Experience in outcomes research and safety assessment in Japan</b> Masato Takeuchi, Kyoto University, Japan	<b>Benzodiazepines, Z-hypnotics and risk of dementia: Special considerations of half-lives and concomitant use - #132</b> Shih Tsung Huang, National Taiwan University, Taiwan
16:15-16:30	<b>Prevalence of aspirin non-responsiveness and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention - #127</b> Sheetal Chauhan, Manipal Academy of Higher Education, India	<b>PMDA's experience of MID-NET utilization for post-marketing drug safety assessment</b> Takashi Ando, Pharmaceuticals and Medical Devices Agency, Japan	<b>Trazodone use and risk of dementia: A population-based cohort study - #133</b> Wallis C.Y. Lau, University College London, UK

16:30-16:45	<b>Statin-associated dose-dependent reductions in non-alcoholic fatty liver diseases among people without any liver disease - #128</b> Sunyoung Cho, Yonsei University, South Korea	<b>How pharmaceutical companies are using RWD for safety assessment</b> Cynthia de Luise, Pfizer, USA  <b>Applying lessons from the US/EU experience to use RWD and produce valid RWE in Japan</b> Soko Setoguchi FISPE, Rutgers University, USA	<b>The association between cholinesterase inhibitors and subsequent cardiovascular events among older patients with Alzheimer's disease in Taiwan - #134</b> Chung-Hsuen Wu, Taipei Medical University, Taiwan
16:45-17:00	<b>Effect of early initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral haemorrhage - #129</b> Ming-Shyan Lin, Chang Gung Memorial Hospital, Taiwan		<b>Acetylcholinesterase inhibitors, cardiosuppressive drugs, and adverse cardiac events in patients with dementia - #135</b> Izumi Sato, Rutgers University, USA; Kyoto University, Japan
17:00-17:15	<b>Effect of synbiotic, probiotic and prebiotic on patients with non-alcoholic fatty liver disease: A systematic review and network meta-analysis - #130</b> Surasak Saokaew, University of Phayao, Thailand		<b>Androgen deprivation therapy and the risk of dementia in Taiwan - #136</b> Chin Yao Shen, National Cheng Kung University, Taiwan
<b>17:15-18:00</b>	<b>Introduction to Asian Pharmacoepidemiology (AsPEN) Symposium</b>		
<b>Room:</b>	Plenary Hall A		
<b>Co-Chairs</b>	<b>Nicole Pratt</b> , University of South Australia, Australia <b>Kiyoshi Kubota FISPE</b> , NPO Drug Safety Research Unit Japan, Japan		
	<p><b>Introduction to AsPEN</b> Nam-Kyong Choi, Ewha Womans University, South Korea</p> <p><b>Examples of AsPEN collaborative work:</b></p> <p style="padding-left: 40px;"><b>Common Data Model in AsPEN</b> Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan</p> <p style="padding-left: 40px;"><b>Example of collaborative projects among AsPEN collaborators</b> Ju-Young Shin, Sungkyunkwan University, South Korea</p> <p><b>AsPEN achievements so far and the way forward</b> Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong</p> <p><b>Panel discussion</b></p>		
18:00	<b>End of day 1</b>		
<b>19:00-22:00</b>	<b>Conference dinner</b>		

## SUNDAY 13 OCTOBER 2019

08:00-09:30	Contributed papers 7 - Statistical methods and signal detection	Symposium 7 - Real World Evidence to support new drug approval and label expansion	Symposium 8 – Post-market surveillance of medicines, vaccines and medical devices across the Asia-Pacific region: The next 10 Years
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Kotonari Aoki</b> , Chugai Pharmaceuticals, Japan <b>Shiro Tanaka</b> , Kyoto University, Japan	<b>K. Arnold Chan FISPE</b> , National Taiwan University, Taiwan	<b>Edward Chia-Cheng Lai</b> , National Cheng Kung University, Taiwan <b>Nam-Kyong Choi</b> , Ewha Womans University, South Korea <b>Kenneth Man</b> , University College London, UK; University of Hong Kong, Hong Kong
08:00-08:15	<b>Caveats on adjustment for additional confounders following insufficient propensity score balancing - #200</b> Tomohiro Shinozaki, Tokyo University of Science, Japan	<b>Overview</b> K. Arnold Chan FISPE, National Taiwan University, Taiwan	<b>Introduction</b> Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan
08:15-08:30	<b>Multiple imputation for survival analysis with missing covariates using non-parametric estimation - #201</b> Yoshinori Takeuchi, The University of Tokyo, Japan	<b>Use cases of Real World Evidence to support drug applications</b> Jeff Lange, Amgen Inc., USA	Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
08:30-08:45	<b>A comparison of structural nested accelerated failure-time models and structural nested mean models for survival outcomes - #202</b> Shiro Tanaka, Kyoto University, Japan	<b>Utilization of Real World Data to support new drug approval: PMDA perspective</b> Yuki Ando, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>AsPEN-Vaccines SIG: Establishing an active vaccine safety monitoring system</b> Nam-Kyong Choi, Ewha Womans University, South Korea
08:45-09:00	<b>Comparison of dynamic treatment regime using inverse probability weighting for dialysis patients - #203</b> Yukari Uemura, National Center for Global Health and Medicine, Japan	<b>How to assess Real World Data quality</b> Wei Zhou FISPE, Merck Research Laboratories, USA	<b>AsPEN-Biologics SIG: Post-marketing safety evaluation of immune check point inhibitor with the use of historical comparator</b> Ju-Young Shin, Sungkyunkwan University, South Korea
09:00-09:15	<b>Analysis of spontaneous adverse event reports derived from real-world EMR data for prospective pharmacovigilance - #204</b> Hyunah Shin, Konyang University Hospital, South Korea	<b>Methodology consideration for using RWE for new drug application and label expansion</b> K. Arnold Chan FISPE, National Taiwan University, Taiwan	<b>AsPEN-Medical device SIG: Identifying predictors of medical device complications using medication prescribing patterns</b> Nicole Pratt, University of South Australia, Australia
09:15-09:30	<b>Evaluation of Tree-based Scan Statistic for drug safety signal detection in a Chinese healthcare database: A Plasmode simulation - #205</b> Hailong Li, Sichuan University, China	<b>Discussion</b>	<b>Panel discussion</b> Session moderators, speakers and Gianluca Trifirò, University of Messina, Italy; Mary-Beth Ritchey FISPE, RTI Health Solutions, USA

<b>09:30-11:00</b>	<b>Morning tea/coffee break with poster discussions</b> Presenters of all original research will be attending their poster during the morning tea break for discussions with interested delegates.		
<b>Room:</b>	Plenary Hall B		
<b>09:45-11:00</b>	<b>Spotlight poster presentations</b> A range of notable poster research reports have been pre-selected, and poster presenters will deliver a three minute description of their work followed by moderated audience discussions.		
	<b>Policy, intervention and validation</b>	<b>Real world safety and effectiveness</b>	<b>Pharmacovigilance and drug safety</b>
<b>Room:</b>	Conference Room 2	Conference Room 3	Craft Classroom
<b>Moderator:</b>	<b>Nam-Kyong Choi</b> , Ewha Womans University, South Korea	<b>Mary-Beth Ritchey FISPE</b> , RTI Health Solutions, USA	<b>Nicole Pratt</b> , University of South Australia, Australia
	<b>Insights of healthcare work-force on establishing medication error reporting system in a tertiary care teaching hospital: A survey questionnaire - #300</b> Sri Harsha Chalasani, JSS College of Pharmacy, India	<b>Effect of antipsychotics use on ischemic stroke in patients with atrial fibrillation and dementia - #311</b> Le Dai, National Taiwan University, Taiwan	<b>Existence of notoriety bias in FDA Adverse Event Reporting System (FAERS) Database and its impact on signal strength - #322</b> Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India
	<b>Current status of re-examination of new drugs on regulatory safety actions in Korea - #301</b> Na-Young Jeong, Ewha Womans University, South Korea	<b>The effectiveness of early use of long-acting injectable antipsychotics in patients with schizophrenia - #312</b> Su-Chen Fang, Taipei City Hospital, Taiwan	<b>Aromatase inhibitors associated with osteonecrosis of Jaw: A disproportionality analysis in the USFDA Adverse Event Reporting System (FAERS) - #323</b> Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India
	<b>Trends and pattern of antibiotic prescriptions for adult outpatients with acute upper respiratory tract infections in Japan, 2008-2018 - #302</b> Lyu Ji, Kyoto University, Japan	<b>The effectiveness of febuxostat in moderate to advanced chronic kidney disease patients with hyperuricemia or gout: A population-based study - #313</b> Chien Huei Huang, National Cheng Kung University Hospital, Taiwan	<b>Population differences in incidence of allopurinol-related severe cutaneous adverse reactions in East Asians - #324</b> Kimie Sai, National Institute of Health Sciences, Japan
	<b>Prevalence of potential drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention - #303</b> Ashwin Kamath, Manipal Academy of Higher Education, India	<b>Longitudinal impact of frailty and polypharmacy on risk of mortality in the elderly: A retrospective cohort study - #314</b> Shih Tsung Huang, National Taiwan University, Taiwan	<b>Anomaly detection as a signal of adverse drug event from claims database: A case example of SGLT2 inhibitors - #325</b> Masato Takeuchi, Kyoto University, Japan
	<b>Impact of drug safety communication on the use of hydroxyethyl starch in Taiwan: An interrupted time series study - #304</b> Chih-Wan Lin, National Taiwan University, Taiwan	<b>Real-world effectiveness of switching from statin monotherapy to ezetimibe/simvastatin combination therapy - #315</b> Tsung Hsuan Lin, Chi Mei Medical Center, Taiwan	<b>Association between diabetes treatment and urinary tract infections: An analysis using data from the JMDC claims database - #326</b> Akiko Tamon, Intage Healthcare Inc., Japan
	<b>Association between pharmaceutical industry payments and prescribing a fixed-dose combination memantine extended released and donepezil: A cross-sectional study - #305</b> Zachary Marcum, University of Washington, USA	<b>Effectiveness of statins for primary prevention of cardiovascular disease in an elderly Asian population - #316</b> Yu-Wen Lin, National Taiwan University, Taiwan	<b>Proton-pump inhibitor use and the risk of progression to end-stage renal disease among chronic kidney disease patients in Taiwan - #327</b> Chih-Jung Tsai, and Chien Huei Huang, National Cheng-Kung University, Taiwan
	<b>Validity assessment of self-reported medication use in a pharmacoepidemiology research (by comparing to medical and pharmacy insurance claims) - #306</b> Minako Matsumoto, Keio University School of Medicine, Japan	<b>Treatment evolution and improved survival in multiple myeloma in Taiwan - #317</b> Yanfang Liu, Global Epidemiology, Janssen Research & Development, Singapore	<b>Undela sheet: One platform for all quantitative signal detection analyses in Pharmacovigilance - #328</b> Krishna Undela, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India

	<b>Impact of pharmacist care in medication handling practices of paediatric dosage forms among caregivers - #307</b> Vasista Sharma, M.S Ramaiah University of Applied Sciences, India	<b>Enoxaparin versus aspirin and aspirin combination in patients with spontaneous intracerebral haemorrhage - #318</b> Sreedharan Nair, Manipal College of Pharmaceutical Sciences, India	<b>Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: A retrospective cohort study - #329</b> Wen Wang, West China Hospital, Sichuan University, China
	<b>Validating the diagnosis of acute stroke in Japanese DPC data from Shiga Stroke and Heart Attack Registry - #308</b> Sachiko Tanaka, Shiga University of Medical Science, Japan	<b>Duloxetine use and risk of coronary artery disease: Systematic review and meta-analysis - #319</b> Kyoungsoon Park, Seoul National University, South Korea	<b>Safety analysis of pneumococcal vaccine in Korea using the KAERS database from 2005 to 2017 - #330</b> SeoungHun You, Chung-Ang University, South Korea
	<b>Regimen and adverse drug reactions of anti-tuberculosis treatment and its associated direct medical costs – a patient cohort-based analysis - #309</b> Biao Xu, Fudan University, China	<b>Combination of glycopeptide and <math>\beta</math>-lactam and risk of acute kidney injury - #320</b> Chi-Hao Shao, National Taiwan University, Taiwan	<b>Predictors and preventability of adverse events following anaesthesia: An active surveillance in a tertiary care hospital - #331</b> Sri Harsha Chalasani, JSS College of Pharmacy, India
	<b>Validation of renal failure diagnosis using laboratory data in the MDV database - #310</b> Naoyuki Yamamoto, CAC Croit Corporation, Japan	<b>Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study - #321</b> Yu-Hsuan Shao, Taipei Medical University, Taiwan	
<b>11:00-12:30</b>	<b>Contributed papers 8 – Adherence and prescription trends</b>	<b>Symposium 9 - Real World Evidence for decision making: Where we are in the Asia Pacific region?</b>	<b>Contributed papers 9 – Validation studies</b>
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Takeo Nakayama</b> , Kyoto University, Japan <b>Edward Lai</b> , National Cheng Kung University, Taiwan	<b>Kiyoshi Kubota FISPE</b> , NPO Drug Safety Research Unit Japan, Japan	<b>Yoshinori Takeuchi</b> , The University of Tokyo, Japan <b>Nam-Kyong Choi</b> , Ewha Womans University, South Korea
11:00-11:15	<b>Medication non-adherence and its predictors among new antihypertensive initiators in Japanese working age patients - #206</b> Shiori Nishimura, The University of Tokyo; Keio University School of Medicine, Japan	<b>Development and use of healthcare databases for safety and effectiveness assessment</b> Solomon Iyasu, MSD, USA	<b>Development and validation of ICD-10-based disease scoring system - #212</b> Young-Jin Ko, Seoul National University College of Medicine, South Korea
11:15-11:30	<b>Adherence, persistence and clinical outcome between generic and brand-name statin users: Retrospective cohort study using Japanese claims database - #207</b> Jingwei Gao, Kyoto University, Japan	<b>RWE generation using healthcare databases by study design in Korea</b> Byung-Joo Park FISPE, Seoul National University College of Medicine, Korea	<b>Development and validation of multi-view inappropriate medication use prescription detection model - #213</b> Zhuo Lin, Peking University, China
11:30-11:45	<b>Participation in randomized controlled trials and subsequent medication adherence and quality of treatment in patients with cardiovascular diseases - #208</b> Natalia Vasyukova, National Medical Research Center for Preventive Medicine, Russian Federation	<b>RWE generation from Industry perspective: How this can inform clinical practice and why Industry needs to collaborate</b> Daniel J. Ruzicka, MSD KK, Japan	<b>Impact of chronological changes in propensity to be exposed a comparison validity in health insurance claim database - #214</b> Daisuke Kato, Keio University; Astellas Pharma Inc., Japan
11:45-12:00	<b>Trends and evaluation of online prescription fill among adults in the United States, 2009-2017 - #209</b> Lin-Ya Yang, Taipei Medical University, Taiwan	<b>PMDA's initiative on real world data utilization for regulatory purposes</b> Yoshiaki Uyama, Pharmaceuticals & Medical Devices Agency, Japan	<b>Validity of claims-based definitions for ulcerative colitis in Japan: Methodology and pilot study results from the Validate-JUC study - #215</b> Sean Gardiner, Pfizer Japan Inc, Japan
12:00-12:15	<b>Adverse drug reactions of Yunnan Baiyao capsule: A multi-center intensive monitoring study in China - #210</b> Bo Li, Beijing Hospital of Traditional Chinese Medicine, Beijing, China		<b>Validity of claims-based definitions for rheumatoid arthritis, selected cancers and infectious diseases in Japan: Results from validate-J study - #216</b> Naonobu Sugiyama, Pfizer, Japan



12:15-12:30	<b>An interrupted time series analysis for use of psychoactive medicines in Japan - #211</b> Tasuku Okui, Kyusyu University Hospital, Japan		<b>Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia's Pharmaceutical Benefits Scheme (PBS) data - #217</b> Benjamin Daniels, University of New South Wales, Australia
<b>12:30-14:00</b>	<b>Lunch with poster discussions</b>		
Room:	Plenary Hall B		
<b>14:00-15:30</b>	<b>Contributed papers 10 – Bone and biologics</b>	<b>Symposium 10 - Lessons learned and future challenges in international signal detection</b>	<b>Symposium 11 – Modern teaching of Pharmacoepidemiology in a 'Big Data' World</b>
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	<b>Satomi Yoshida</b> , Kyoto University, Japan <b>Jung-Won Park</b> , Yonsei University, Republic of Korea	<b>Richard Hill</b> , Therapeutic Goods Administration, Australia <b>Andrew Bate</b> , Pfizer, UK	<b>Robert W. Platt</b> , McGill University, Canada
14:00-14:15	<b>Anti-osteoporosis treatment pattern after hip or vertebral fractures among postmenopausal women in China - #218</b> Hongxin Zhao, Shanghai Synyi Medical Technology Co., Ltd, China	<b>Introduction</b> Richard Hill, Therapeutic Goods Administration, Australia	<b>Teaching the fundamentals of pharmacoepidemiology in a 'Big Data' world</b> Kristian Filion, McGill University, Canada
14:15-14:30	<b>Changes of National Health Insurance reimbursement criteria on drug prescribing patterns and medical expenditures of osteoporotic fractures - #219</b> Chen-Yu Wang, National Taiwan University, Taiwan	<b>Signal detection in distributed health data networks in the US: Lessons, barriers, and opportunities</b> Jeffrey Brown, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	<b>The use of platforms for teaching pharmacoepidemiology</b> Seoyoung C. Kim, Harvard Medical School, USA
14:30-14:45	<b>Osteoporotic fractures associated with the use of rivaroxaban vs warfarin or dabigatran among patients with atrial fibrillation - #220</b> Wallis Lau, UCL School of Pharmacy, UK; The University of Hong Kong, Hong Kong	<b>Signal detection for drug safety using Japanese Real World Data</b> Chieko Ishiguro, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	<b>What pharmacoepidemiologists need to learn about machine learning</b> Nicole Pratt, University of South Australia, Australia
14:45-15:00	<b>A database study of clinical features and treatment patterns with biologics in patients with Crohn's disease in Japan - #221</b> Yanfang Liu, Janssen Research & Development, Singapore	<b>Multiple data stream surveillance for Real World Evidence generation</b> Andrew Bate, Pfizer, UK	<b>The use of distributed research network for teaching pharmacoepidemiology</b> Rae Woong Park, Ajou University, South Korea
15:00-15:15	<b>Prevalence, safety and long-term retention rates of biologics in Hong Kong from 2001 to 2015 - #222</b> Mengqin Ge, Li Ka Shing Faculty of Medicine, Hong Kong		
15:15-15:30	<b>Safety regarding infectious events of biosimilars compared to other drugs in rheumatoid arthritis: A systematic review and network meta-analyses - #223</b> Yao Chen, Peking University, China		<b>Discussion</b>
<b>15:30-16:15</b>	<b>Afternoon tea/coffee break</b>		
Room:	Plenary Hall B		

## SUNDAY 13 OCTOBER 2019 continued

16:15-17:45	Contributed papers 11 – Cancer	Symposium 12 – Challenges and approaches to Pharmacoepidemiologic research in mental health	Symposium 13 – A new international collaboration to advance medication safety in people with neurodegenerative diseases: NeuroGEN
<b>Room:</b>	Conference Room	Plenary Hall A	Exhibition Hall A
<b>Chair/ Moderator:</b>	<b>Azusa Hara</b> , Keio University, Japan <b>Yea-Huei Kao Yang FISPE</b> , National Cheng Kung University, Taiwan	<b>Soko Setoguchi FISPE</b> , Rutgers University, USA	<b>Ian Wong</b> , The University of Hong Kong, Hong Kong <b>Simon Bell</b> , Monash University, Australia
16:15-16:30	<b>Estimation of healthcare costs for multiple myeloma in Japan using a nationwide claims database - #224</b> Jia Guan, Kyoto University, Japan	<b>Introduction</b> Tobias Gerhard FISPE, Public Health Rutgers University, USA	<b>Global collaboration to advance medication safety: Challenges, opportunities and where to from now?</b> Ian Wong, The University of Hong Kong, Hong Kong Simon Bell, Monash University, Australia  <b>Case study from the UK: Transforming a single country study into an international study</b> Wallis Lau, University College London, UK  <b>Case study from Australia: Investigating medication use and safety using only medication data</b> Jenni Ilomaki, Monash University, Australia  <b>Development of distributed network structures for NeuroGEN studies</b> Edward Lai, National Cheng Kung University, Taiwan
16:30-16:45	<b>Use of Phosphodiesterase 5 inhibitors reduces risk of colorectal cancer in men with benign colorectal neoplasms - #225</b> Jianguang Ji, Lund University, Sweden	<b>Mortality risk of antipsychotic augmentation for depression</b> Tobias Gerhard FISPE, Public Health Rutgers University, USA	
16:45-17:00	<b>Compare effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan - #226</b> Yan-Lin Wang and Kai-Cheng Chang, Linkou Chang Gung Memorial Hospital, Taiwan	<b>Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD)</b> Ju-Young Shin, Sungkyunkwan University, South Korea	
17:00-17:15	<b>Comparative efficacy and safety of angiogenesis inhibitors in the treatment of non-small cell lung cancer: Systematic review and network meta-analysis - #227</b> Kirati Kengkla and Surasak Saokaew, University of Phayao, Thailand	<b>Comparative mortality associated with ziprasidone and olanzapine (ZODIAC)</b> Brian Strom FISPE, Rutgers University, USA	
17:15-17:30	<b>Comparing effectiveness of first-line tyrosine kinase inhibitors in advanced lung adenocarcinoma patients with EGFR mutation using real-world data - #228</b> Yi-Hsin Yang, National Institute of Cancer Research, Taiwan	<b>Questions and discussion</b> moderated by Soko Setoguchi FISPE, Rutgers University, USA	
17:30-17:45			
<b>17:45-18:00</b>	<b>Closing, farewell and Award ceremony</b>		
<b>Room:</b>	Plenary Hall A		
<b>Chair:</b>	<b>Shiro Tanaka</b> , Local Host Committee, Kyoto University, Japan		
	<b>Frank May FISPE</b> , ACPE12 Conference Co-Chair <b>James Vrac</b> , Executive Secretary, International Society for Pharmacoepidemiology; <b>Presentation of 'Rising Star' Award:</b> <b>Ms Samanta Lalic</b> , Centre for Medicine Use and Safety, Monash University, Parkville, Australia, and Pharmacy Department, Austin Health, Melbourne, Australia 'Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia' - #103 <b>Announcement of the Seoul ACPE13 meeting – 15-17 October 2020</b> Jung-Won Park and Nam-Kyong Choi		
<b>18:00</b>	<b>End of day 2</b>		